Head and Neck Cancer Pharmaceutical Drug and Healthcare Pipeline Review H2

Feb 28, 2017

WiseGuyReports.com adds Exclusive Research on “Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016” reports to its database.

Pune, India - February 28, 2017 /MarketersMedia/ —

Head and Neck Cancer Squamous Cell Carcinoma is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/740561-head-and-neck-cancer-squamous-cell-carcinoma-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 49, 49, 2, 23, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 2 molecules, respectively.Head And Neck Cancer Squamous Cell Carcinoma.

Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline

Table of Content: Key Points
Table of Contents 2
Introduction 6
Head And Neck Cancer Squamous Cell Carcinoma Overview 7
Therapeutics Development 8
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 10
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 17
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 18
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 22
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 32
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 33
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 118
Drug Profiles 148

Access Report @ https://www.wiseguyreports.com/reports/740561-head-and-neck-cancer-squamous-cell-carcinoma-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: Norah Trent
Email: [email protected]
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349

Source URL: http://marketersmedia.com/head-and-neck-cancer-pharmaceutical-drug-and-healthcare-pipeline-review-h2/173800

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 173800

More News

aritcles[0].caption
Sep 30, 2026

Trump finds close ally in Nvidia’s Huang at key AI juncture

Nvidia CEO Jensen Huang is becoming one of President Trump’s fiercest allies on AI at a critical juncture for the industry. In the face of mounting concerns over the future of AI, Huang is one of the few tech executives standing fully behind the president’s push to continue full steam ahead on AI, while others...


article.head.headline
Sep 30, 2026
Gone ‘rogue’ and set to kill us all? Please. I know the banal truth

There’s snake-oil being sold to us and much of the world is falling for it.

article.head.headline
Sep 29, 2026
Trump, GOP leaders look to reclaim control over AI narrative

President Trump and Republicans are seeking to reclaim control of the narrative surrounding artificial intelligence as Democrats use the issue to go on offense ahead of the midterms. Numerous tech leaders joined Trump and Speaker Mike Johnson (R-La.) at a Tuesday luncheon on “super intelligence” — the president’s new term for AI — where they...

article.head.headline
Sep 29, 2026
5 things to know about Trump's new AI website

President Trump launched America.gov on Tuesday, a website that uses artificial intelligence to help Americans find information across government websites with a single search. Trump said the website has been in the works since the early days of his second term and that it’s still a work in progress. The website's unveiling took place at...

article.head.headline
Sep 29, 2026
AI firms sign 'morally binding' self-policing pledge in White House meeting

Key AI industry leaders signed onto a pledge Tuesday to self-police development, President Trump and Speaker Mike Johnson (R-La.) announced following a meeting at the White House. The agreement, called "The White House Accord on Superintelligence Joint Commitment on Frontier SI Responsibilities,” lays out a series of voluntary commitments for AI developers, Johnson explained. Trump...

article.head.headline
Sep 29, 2026
What would Jon Husted's data center bill actually do?

Sen. Jon Husted’s (R-Ohio) Ratepayer Protection Act aims to mitigate high electricity costs associated with data centers, but even if it passes, it’s not clear if the bill would have any impact. The legislation, which easily cleared the House 417-3, requires states and some electric utilities to consider a standard under which data centers would...

article.head.headline
Sep 29, 2026
Trump to sign order renaming AI as 'superintelligence'

President Trump plans to sign an order Tuesday officially renaming AI as “superintelligence.” “We're going to be signing a document today at about 5 o'clock, renaming artificial intelligence because it's not artificial,” Trump said in public remarks, after hosting a luncheon with top technology executives at the White House. “We all agree on that, and...

article.head.headline
Sep 29, 2026
Rubio: New US site lets Americans apply online for passport

President Trump’s new artificial intelligence website allows for Americans to apply for passports online, Secretary of State Marco Rubio said Tuesday. During a presentation announcing America.gov on Tuesday, Rubio derided the previous process of applying for and receiving a passport. “I think you would agree that American citizens deserve better than this, and that's why...

article.head.headline
Sep 29, 2026
Cruz blocks push by Democrats to unanimously pass AI safety bill

Sen. Ted Cruz (R-Texas) blocked an effort by Democrats on Tuesday to pass legislation creating an AI safety panel tasked with evaluating and creating enforceable standards for frontier models. Cruz, who chairs the Senate Commerce Committee, objected to an attempt by Sens. Mark Warner (D-Va.), Brian Schatz (D-Hawaii) and Andy Kim (D-N.J.) to pass the...

article.head.headline
Sep 29, 2026
Schumer slams data center bill as 'ineffectual participation trophy'

Senate Minority Leader Chuck Schumer (D-N.Y.) on Tuesday slammed a bill that would force states to consider standards to mitigate data centers' power price impacts as an "ineffectual participation trophy." His comments signal that Democrats could try to block the bill, which the Senate is expected to take up this week. "Americans are demanding real...

article.head.headline
Sep 29, 2026
Trump launches America.gov, AI-powered government services hub

President Trump launched a website Tuesday that uses artificial intelligence to help Americans navigate the federal government and find information and services. Trump touted the website, America.gov, during an event at the Andrew W. Mellon Auditorium in Washington. He thanked Joe Gebbia, the Airbnb co-founder who now leads the National Design Studio and serves as...

article.head.headline
Sep 29, 2026
New Mexico venture studio unveils quantum lab to boost US tech edge 

The investment and incubation firm Roadrunner Venture Studios will unveil a new quantum lab Tuesday in Albuquerque as New Mexico looks to bolster the U.S.’s position in the global race for quantum computing. The Roadrunner Quantum Lab will open as part of the state's $450 million commitment to quantum development. Those behind the project say...


YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

The World Insiders
ABOUT US

The World Insiders brings you exclusive coverage from across the globe in a timely, easy to consume format sourced directly from our regional media partners.